BACKGROUND: Persistent infection with oncogenic human papillomavirus (HPV) types-16 and -18 is an established cause of cervical and other cancers. Some studies report detection of oncogenic HPV DNA in colorectal carcinomas, with prevalence estimates as high as 84%. However, other studies report detecting no HPV DNA in colorectal tumors. METHODS: To evaluate the prevalence of HPV in colorectal cancer subsets, we conducted a case-case comparison study. This study included 555 cases of incident colorectal cancer from the Seattle Colon Cancer Family Registry (CCFR), ages 20 to 74 years and diagnosed between 1998 and 2002. Standardized interviews were used to elicit demographics and risk factor data. Tumor DNA was assayed for HPV-16 and -18 DNA using real-time PCR. Microsatellite instability (MSI) status was assessed using a standard 10-marker panel and confirmed with immunohistochemical staining. Prevalence estimates were calculated for the overall sample, and stratified by patient and tumor characteristics. Fisher exact test was used to compare prevalence between strata. RESULTS: HPV-16 DNA was detected in 2% of colorectal tumors, but no HPV-18 DNA was detected. HPV-16 prevalence did not vary between cases according to sex, age, race, smoking-status, or MSI-status (P > 0.05). HPV-16 prevalence in rectal carcinomas was 5% compared with 1% in colon carcinomas (P = 0.03). CONCLUSIONS: Among a large sample of colorectal carcinomas, prevalence of HPV-16 and -18 was very low. Prior studies detecting high HPV prevalence in colorectal carcinomas are likely the result of contamination from the anal canal or clinical processing. IMPACT: HPV is unlikely to play a large role in colorectal carcinogenesis.
BACKGROUND: Persistent infection with oncogenic human papillomavirus (HPV) types-16 and -18 is an established cause of cervical and other cancers. Some studies report detection of oncogenic HPV DNA in colorectal carcinomas, with prevalence estimates as high as 84%. However, other studies report detecting no HPV DNA in colorectal tumors. METHODS: To evaluate the prevalence of HPV in colorectal cancer subsets, we conducted a case-case comparison study. This study included 555 cases of incident colorectal cancer from the Seattle Colon Cancer Family Registry (CCFR), ages 20 to 74 years and diagnosed between 1998 and 2002. Standardized interviews were used to elicit demographics and risk factor data. Tumor DNA was assayed for HPV-16 and -18 DNA using real-time PCR. Microsatellite instability (MSI) status was assessed using a standard 10-marker panel and confirmed with immunohistochemical staining. Prevalence estimates were calculated for the overall sample, and stratified by patient and tumor characteristics. Fisher exact test was used to compare prevalence between strata. RESULTS:HPV-16 DNA was detected in 2% of colorectal tumors, but no HPV-18 DNA was detected. HPV-16 prevalence did not vary between cases according to sex, age, race, smoking-status, or MSI-status (P > 0.05). HPV-16 prevalence in rectal carcinomas was 5% compared with 1% in colon carcinomas (P = 0.03). CONCLUSIONS: Among a large sample of colorectal carcinomas, prevalence of HPV-16 and -18 was very low. Prior studies detecting high HPV prevalence in colorectal carcinomas are likely the result of contamination from the anal canal or clinical processing. IMPACT: HPV is unlikely to play a large role in colorectal carcinogenesis.
Authors: Victoria M Chia; Polly A Newcomb; Jeannette Bigler; Libby M Morimoto; Stephen N Thibodeau; John D Potter Journal: Cancer Res Date: 2006-07-01 Impact factor: 12.701
Authors: Anthony S Gunnell; Trung N Tran; Anna Torrång; Paul W Dickman; Pär Sparén; Juni Palmgren; Nathalie Ylitalo Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10-20 Impact factor: 4.254
Authors: Laura Lorenzon; Mario Ferri; Emanuela Pilozzi; Maria Rosaria Torrisi; Vincenzo Ziparo; Deborah French Journal: Int J Colorectal Dis Date: 2010-09-01 Impact factor: 2.571
Authors: Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky Journal: J Med Virol Date: 2009-04 Impact factor: 2.327
Authors: Renske D M Steenbergen; Jillian de Wilde; Saskia M Wilting; Antoinette A T P Brink; Peter J F Snijders; Chris J L M Meijer Journal: J Clin Virol Date: 2005-03 Impact factor: 3.168
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: Boudewijn J M Braakhuis; Peter J F Snijders; Willem-Jan H Keune; Chris J L M Meijer; Henrique J Ruijter-Schippers; C René Leemans; Ruud H Brakenhoff Journal: J Natl Cancer Inst Date: 2004-07-07 Impact factor: 13.506
Authors: Larisse Silva Dalla Libera; Thalita de Siqueira; Igor Lopes Santos; Jéssica Enocencio Porto Ramos; Amanda Xavier Milhomen; Rita de Cassia Gonçalves de Alencar; Silvia Helena Rabelo Santos; Megmar Aparecida Dos Santos Carneiro; Rosane Ribeiro Figueiredo Alves; Vera Aparecida Saddi Journal: PLoS One Date: 2020-06-25 Impact factor: 3.240